Komori
ReproCELL (4978) · RiskMitigated

Impact of COVID-19 on Research and Business Activities

First written in FY2020. 8 of 16 entries say "Mitigated", first in FY2021-Q2. Latest entry: FY2026.

16entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY2023-Q2MitigatedFY2023-Q3 – FY20262020: 320202021: 420212022: 320222023: 420232024: 120242025: 020252026: 12026
Same theme, other companies
Clinical Trial Delays and Trial Impact from COVID-19A theme 21 companies write about · 21 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2022: 4 of 20 companies on the "Worse" side.

6 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 21 companies compared. The sentences above are computed from all 21.
Full recordFilings, disclosures and news, newest first
  1. FY2026MitigatedAnnual report

    「The business environment has also returned toward its pre-pandemic state.」

    While the possibility remains that the impact of infectious diseases may occur periodically, the decline in the likelihood of restrictions on activities and the recovery of the business environment toward its pre-pandemic state have been reaffirmed.
  2. FY2024-Q3MitigatedAnnual report

    「Although the spread of infection may continue to occur periodically, the likelihood of restrictions on activities of the kind previously imposed has declined as vaccination rates have risen. The business environment has also returned toward its pre-pandemic state.」

    While the possibility of further outbreaks remains, the decline in the likelihood of restrictions on activities and the recovery of the business environment toward its pre-pandemic state have been reaffirmed.
  3. FY2024-Q2MitigatedAnnual report

    「Although the spread of infection may continue to occur periodically, the likelihood of restrictions on activities of the kind previously imposed has declined as vaccination rates have risen. The business environment has also returned toward its pre-pandemic state.」

    While the possibility of further outbreaks remains, the decline in the likelihood of restrictions on activities and the recovery of the business environment toward its pre-pandemic state have been reaffirmed.
  4. FY2024-Q1MitigatedAnnual report

    「Although the spread of infection may continue to occur periodically, the likelihood of restrictions on activities of the kind previously imposed has declined as vaccination rates have risen. The business environment has also returned toward its pre-pandemic state.」

    While the possibility of periodic outbreaks remains, the decline in the likelihood of restrictions on activities and the recovery of the business environment toward its pre-pandemic state are described.
  5. FY2023MitigatedAnnual report

    「The business environment has also returned toward its pre-pandemic state.」

    While the possibility remains that the impact of COVID-19 may occur periodically, it is recognised that the business environment has returned toward its pre-pandemic state as vaccination rates have risen and restrictions on activities have been reduced.
  6. FY2023-Q3MitigatedAnnual report

    「The spread of COVID-19, which began in 2020, continues around the world, while restrictions on activities are gradually being eased in preparation for living with COVID-19, and the business environment is returning toward its pre-pandemic state.」

    It is recognised that, although the impact of the pandemic continues, restrictions on activities are being eased and the business environment is returning toward its pre-pandemic state.
  7. FY2023-Q2RestatedAnnual report

    「The spread of COVID-19, which began in 2020, continues around the world, while restrictions on activities are gradually being eased in preparation for living with COVID-19. However, uncertainty may continue in the future due to the emergence of new variants and other factors.」

    While restrictions on activities are gradually being eased, the possibility that uncertainty will continue due to the emergence of new variants and other factors has been reaffirmed.
  8. FY2023-Q1RestatedAnnual report

    「The spread of COVID-19, which began in 2020, continues around the world, while restrictions on activities are gradually being eased in preparation for living with COVID-19. However, uncertainty may continue in the future due to the emergence of new variants and other factors.」

    While restrictions on activities are gradually being eased, the possibility that uncertainty will continue due to the emergence of new variants and other factors has been reaffirmed.
  9. FY2022-Q3RestatedAnnual report

    「The spread of COVID-19, which began in 2020, continues in countries around the world. Vaccination is progressing in each country, but uncertainty may continue in the future, partly due to the impact of the new Omicron variant.」

    While progress in vaccination is described, the possibility that uncertainty surrounding the pandemic, including the impact of the Omicron variant, will continue has been reaffirmed.
  10. FY2022-Q2RestatedAnnual report

    「The spread of COVID-19, which began in 2020, continues in countries around the world. Vaccination is progressing in each country, but considerable uncertainty remains regarding forecasts of infection trends, and the impact of COVID-19 may continue in the future.」

    While progress in vaccination is described, uncertainty remains regarding forecasts of infection trends, and the possibility that the impact of COVID-19 will continue has been reaffirmed.
  11. FY2022-Q1RestatedAnnual report

    「However, there remains considerable uncertainty regarding the spread of COVID-19 and vaccination rates in each country, and the impact of COVID-19 may continue in the future.」

    The uncertainty surrounding the spread of COVID-19 and vaccination rates, and the possibility that its impact will continue in the future, have been reaffirmed.
  12. FY2021MitigatedAnnual report

    「In the first quarter of the current fiscal year, a state of emergency was declared in Japan and lockdown measures were imposed in countries overseas, resulting in a substantial temporary impact. Although a recovery trend emerged from the second quarter onward, the spread of infection was not brought under control, and the fiscal year as a whole was heavily affected by COVID-19.」

    Although a substantial impact actually occurred in the first half of the current fiscal year, a recovery trend emerged from the second quarter onward, and mitigation of the impact is described.
  13. FY2021-Q3RestatedAnnual report

    「The impact of COVID-19 continued in the first quarter of the current fiscal year, but signs of recovery have emerged since the second quarter. From the fourth quarter onward, we will continue to promote our business actively while thoroughly implementing measures to prevent the spread of infection.」

    The policy has been reaffirmed that, following the impact of COVID-19 through the first quarter, signs of recovery emerged from the second quarter and the business would be promoted while continuing measures to prevent the spread of infection.
  14. FY2021-Q2MitigatedAnnual report

    「The impact of COVID-19 continued in the first quarter of the current fiscal year, but signs of recovery have emerged since the second quarter. From the third quarter onward, we will continue to promote our business actively while thoroughly implementing measures to prevent the spread of infection.」

    It is stated that, following the impact of COVID-19 through the first quarter, signs of recovery emerged from the second quarter and the business would be promoted while continuing measures to prevent the spread of infection.
  15. FY2021-Q1MaterialisedAnnual report

    「Our business is not inherently affected by COVID-19, but it has experienced a temporary impact in the first half of the current consolidated fiscal year due to lockdowns and other measures.」

    It is stated that lockdowns and other measures actually had a temporary impact on business activities in the first half of the current consolidated fiscal year. While the accounting assumptions are based on a recovery in the second half, uncertainty over when the situation will be brought under control is also disclosed.
  16. FY2020First statedAnnual report

    「We believe that our business is inherently unlikely to be affected by COVID-19. However, research activities at the universities and pharmaceutical companies that are our customers have been temporarily restricted, and we expect the research support business to be affected in the short term.」

    It is stated that the spread of COVID-19 temporarily restricted research activities at universities and pharmaceutical companies, resulting in a short-term impact on the research support business.
Moved together

"Risk of delayed elimination of accumulated deficits" moved the same way as this thread, in the same document, in 6 of its 16 moves.

665444★123456
  1. ★This thread
  2. 1Risk of delayed elimination of accumulated deficits6×
  3. 2Impact of exchange-rate fluctuations on profit or loss and goodwill6×
  4. 3Research Support Business Segment Turning Profitable5×
  5. 4Global Development of Regenerative Medicine Products in Compliance with Japanese, U.S. and European Regulatory Requirements4×
  6. 5Development and Supply of an iPS Cell Bank for Clinical Applications4×
  7. 6Incentives for Directors and Employees to Enhance Corporate Value Through Restricted Stock Compensation4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for ReproCELL yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.